InteKrin

About:

InteKrin Therapeutics is focused on developing and commercializing therapeutics for neuroendocrine, metabolic and immune disorders.

Website: http://www.intekrin.com

Top Investors: OrbiMed, Vivo Capital, Asset Management Ventures (AMV), Sofinnova Investments, Amgen Ventures

Description:

InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.

Total Funding Amount:

$66.4M

Headquarters Location:

Los Altos, California, United States

Founded Date:

2005-01-01

Contact Email:

info(AT)intekrin.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2010-06-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai